Next Phase Newsletter

A social impact investment fund with offices in Europe and the United States fund was launched with a total of $108 million in capital to invest into companies that are improving the quality of lives in low-income countries through the eradication of preventable diseases. The firm looks to allocate anywhere from $3+ million into companies with the ability to allocate up to $15 million over the lifetime of the investment. The firm primarily looks to provide mezzanine debt financing although they can be very flexible in terms of capital structure. The firm is actively reviewing opportunities and is open to invest in companies from around the globe.

The firm is currently looking for companies developing therapeutics, diagnostics, and medical devices. The firm is looking for companies targeting the full spectrum of global diseases including cholera, diarrhea, HIV, malaria, and TB, as well as products for improving global nutrition, maternal health and family planning. The firm is looking for companies that have POC data in humans and require financing to complete their trials, gain country regulatory approval and begin commercialization.

The firm is looking for private or public companies with an experienced management team. The firm looks to take a board/observer seat on a case by case basis in companies where they can add strategic value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office with offices in the Northeast and Midwestern United Sates invests its principal capital into high growth companies in both the private and public sectors. The firm’s investment size is highly variable and dependent on the financial needs of the company. The firm often leads investment rounds and also has the ability to leverage its additional network of high-net worth families and like-mined co investors to syndicate for larger deals as well as follow on investments.  The firm looks to invest in companies throughout the United States and has no set number of investments in plans to make, however they are actively reviewing new opportunities.

Within healthcare, the firm is most interested in companies developing devices and diagnostics. The firm is looking for companies devices that solve a significant medical problem with strong IP. The firm is willing to invest in companies from the prototype stage to those that already have their product on the market and is generally agnostic in terms of indication. Historically the firm has invested in companies working with cardiac devices and also has held special interest in the pediatrics space. The firm is generally not as interested in consumer facing devices. The firm is also willing to consider investments in the Therapeutics space though this area is less of a focus.

The firm is looking for companies that have experienced management teams and a strong board behind them. The firm is willing to invest in both privately and public held companies, with special interested in making PIPE investments. The firm looks to take a board seat into companies on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm is looking to make direct equity investments into life science companies ranging from $5-25m, primarily in the USA and Europe, with the potential to invest in other areas if the right syndication opportunities are available.  The firm typically makes 10 new direct investments per year across a diverse range of sectors, including healthcare IT, therapeutics and medical devices.  The firm leads or co-leads financing rounds in about 60% of cases and takes a board seat in these instances, but on other occasions may syndicate with other investors and not take a board seat.

The firm prefers to invest in medical devices and therapeutics with the potential to become the standard of care in a large clinical area with unmet needs.  Focus indications include oncology, immunology, cardiology, diabetes, neurology, infectious diseases, respiratory disorders, pain management and psychiatry.  The firm prefers to invest in the later clinical stages (Phase II + III), but will consider opportunistic investments in earlier stage opportunities if the firm sees the potential for outsized risk-adjusted returns due to a market dislocation.

The firm also invests in healthcare IT companies that have a product already on the market and have attained revenue and customer adoption.  These investments are in a variety of market segments, including enterprise software, clinical management software, connected devices/equipment and direct-to-consumer products.

In the therapeutic and medical device sectors, the firm seeks to invest in companies with unique intellectual property and with strong investor syndicates who can fund late-stage clinical trials to completion.  In the healthcare IT sector, the firm prefers to invest in companies with at least $5m in revenue and strong, experienced management teams.  The firm performs thorough due diligence, looking at factors such as historical performance, size of market opportunity, revenue per customer and customer stickiness in addition to vetting the product itself and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital fund of a large insurance provider is looking to make private investments in the healthcare space ranging from $5 – $15 million in stages ranging anywhere from seed to buyout. The firm looks to invest in companies of strategic interested to its parent also seeking strong financial returns. The firm is willing to look at opportunities around the globe.

Within healthcare the firm is looking to invest in sectors of healthcare IT, services, and diagnostics and to a lesser extent wearable devices. The firm is most interested in companies that are have reached or are very near FDA approval and are targeting large market indications.

The firm looking for companies with experienced management teams and prefer working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm funded entirely by its partners based in the United States is looking to make equity investment into early and mid-stage life science companies ranging from $500,000 to 2 million initially. The firm looks to get involved in seed and series A rounds. The firm could make as many as 6 investments over the next 12 months and looks to invest in companies located throughout the United States, Europe and Israel.

The firm is currently interested in sectors of Therapeutics, and Diagnostics. The firm is open to review all types of molecules and platforms and is currently most interested in for companies working towards indications of autism, CNS disorders, and Parkinson’s disease. The firm generally looks to get involved with companies that are at the pre-clinical stage of development.

The firm is looking for companies with driven, and talented management teams with strong IP for their products. The firm is looking to invest in privately held companies and looks to take an active role following investment generally as a member of the board. The firm is very comfortable working with scientific founding teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities. The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including immunology, oncology, MS, and fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase I of clinical trials. The firmis looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm located in the Northeastern United Sates is looking to make investments in the life sciences space, and does so on a case by case basis without a traditional fund structure. Since the members are investing their own capital, the investment size and capital structure are highly flexible and will depend on the financial needs of the company. However the minimum amount the fund is willing to invest is $2 million, and can go upwards of $40 million. The firm invests in private or public companies and prefers to be the lead investor, but is open to syndicate as well. The firm is willing to invest in opportunities from all across the Globe. The firm is looking to conduct as many investments as possible over the course of the next 12 months, and is open to qualified deal flow

The firm is very opportunistic and will consider a broad range of life science opportunities. The firm will consider biotech, medical technology, R&D services, however the firm prefers not to invest in healthcare IT, dermatology, or wound care. The firm focuses on companies with clinical assets with some efficacy data, through those who have products on the market are also considered. The firm has a strong interest in technologies that significantly improve the standard of care.

The firm evaluates the company’s management team on a case by case basis. The firm is open to working with both experienced teams, as well as new entrepreneurs, and only requires that the team be competent. The firm does not require a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com